🇺🇸

US SEC Filing Intelligence

· daily

US IPO Pipeline SEC S-1 Filings — October 27, 2026

This IPO Pipeline stream covers seven SEC filings dated October 27, 2026, dominated by capital-raising registrations (S-1s) from distressed or thinly capitalized issuers rather than clean IPO candidates. Five of the seven filings carry negative or mixed sentiment with explicit going-concern, material-weakness, or no-minimum-proceeds language, and the excerpts provided contain few quantitative period-over-period results, so trend analysis is limited to what the filings disclose. The most material developments are Splash Beverage Group's dilution overhang (roughly 11.3M shares on preferred conversion plus a 20% RSU grant pending approval, against a stock range of $0.135 to $3.92 post reverse split) and Bionano Genomics' going-concern warning requiring significant financing within 12 months. Imunon's best-efforts raise has no minimum proceeds, and Aupenheim's $1.6M self-underwritten offering carries PRC-related regulatory risk. The Twin Vee/USFM merger (S-4) and the Heroic Empire blank-check SPAC (S-1) are the more structured transactions, with defined trust sizes, cross-conditioned votes, and lock-up terms. Portfolio-level pattern: capital is being raised on dilutive, contingent terms, and proceeds certainty is weak across the pipeline.

7 high priority 7 total filings
· daily

US SEC Trading Suspension Halt Orders — October 27, 2026

Five filings dated 2026-10-27 span Nasdaq listing-compliance actions and one voluntary exchange migration, all within the trading suspension, delisting, and regulatory halt scope. The dominant theme is sub-$1.00 bid price and minimum-value deficiencies forcing small-cap issuers toward delisting or compliance extensions: Rekor Systems received a 180-day extension to April 26, 2027, Advasa Holdings faces an April 19, 2027 deadline after 30 consecutive business days below $1.00, and NextNRG is in the most severe position, with a delisting determination already issued and a Nasdaq Hearings Panel decision pending after an October 22, 2026 hearing. Socket Mobile is leaving Nasdaq Capital Market voluntarily for OTCID, with last Nasdaq trading expected November 18, 2026 and OTCID quotation starting around November 19, 2026, citing a stockholders' equity shortfall flagged August 24, 2026. The filings contain limited period-over-period financial data, so trend quantification is restricted to listing-standard thresholds and dated compliance timelines rather than revenue or margin comparisons. General Motors' bylaw amendment is governance-only and largely immaterial to the suspension and delisting theme.

5 high priority 5 total filings
· daily

US Executive Officer Management Changes SEC — October 27, 2026

Across the 38 filings for the USA Executive & Director Changes stream (period 2026-10-27), the dominant theme is CFO and senior finance leadership turnover, with at least eight finance-chief transitions or interim appointments (Visteon, Goodyear, Axcelis, Hycroft, Visteon-linked Goodyear hire, Lifeward, TV Channels Network, Resources Connection) and several accounting-officer reshuffles at Ares-affiliated funds. Board refreshment is the second theme, with new independent directors added at Amgen, Better Home & Finance, Altimmune, Entera Bio, BlackBerry, Cooper Companies, Hycroft and Ares-related vehicles, often paired with director resignations or retirements. Most filings state no disagreement with operations, policies or practices, which lowers the probability of hidden governance conflict, though Cooper Companies' CEO exit alongside a reaffirmed guidance that 'has not met management's expectations' is the clearest governance-stress event. Period-over-period financial data is largely absent from these governance-focused 8-Ks, so the quantitative read-through is concentrated in Xylem (orders +7% reported, revenue -3%, FY guidance cut) and Cooper Companies. Market implication: finance-function continuity risk is elevated for several mid-caps during Q4 close and 2027 planning, and investors should track interim-to-permanent CFO timelines and any further CEO/board changes at Cooper.

38 high priority 38 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 27, 2026

This digest covers 38 filings tied to the USA Board Room Changes stream (Officer Change, Director Change, Board Change), dated October 27, 2026. The dominant theme is C-suite and finance-leadership turnover: at least a dozen CFO, CAO, COO, CCO or CEO transitions, with several interim CFO appointments (Visteon, Axcelis, TV Channels, Resources Connection, Hycroft's planned transition) that point to near-term execution risk during reporting cycles. Board refreshment is equally visible, with new independent directors at Amgen, Better Home & Finance, Entera Bio, Altimmune, BlackBerry, Hycroft and FHLB Indianapolis, generally read as governance hygiene rather than distress. The most material event is Cooper Companies, where the CEO was removed and an independent director installed as Executive Chair while guidance was reaffirmed despite acknowledged underperformance. Xylem's Q3 2026 print is the main quantitative datapoint in scope: orders up 7% reported and 10% organic, revenue down 3% reported and flat organically, adjusted EPS guidance cut to $5.40-$5.45 from $5.55-$5.70, and a divestiture-driven three-segment restructuring effective January 1, 2027. Most filings disclose no period-over-period financial data, so the enriched comparison fields are sparse across this batch; conclusions below rely primarily on governance and compensation disclosures. Several filings carry non-financial enriched data only, and where a classification is ambiguous (e.g., CCO Holdings, Charter preferred dividend) it has been flagged rather than forced.

38 high priority 38 total filings
· daily

USA Insider Trading Pulse — October 27, 2026

The 'USA Insider Trading Pulse' digest covers 50 SEC Form 4 insider filings dated 2026-10-27. The dominant pattern is routine equity-compensation activity rather than discretionary conviction: a large share of filings are director annual share awards (Park National's board received 301-share grants across roughly ten directors), officer tax withholdings on vesting RSUs (Ingram Micro at $27.50, JAKKS Pacific at $30.52, Frontier Group at $4.94), and Toyota's modest officer/director awards at $19.87. Discretionary open-market activity is concentrated in a small set of names: open-market buys by Pluri's director (~$1.25M), Northpointe's Chairman & CEO (~$1.5M across two 50,000-share purchases), KKR Income Opportunities' Treasurer/CFO (~$78K), Agora's CEO under a 10b5-1 plan, and Ategrity's director. Open-market sales were modest and largely tied to 10b5-1 plans or the same director (Kyriakopoulos at EuroDry, Euroseas and Euroholdings). Period-over-period comparison fields were not populated in the source data, so trend and margin analysis cannot be quantified from these filings; conclusions below rest on transaction size, post-trade holdings and materiality scores.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — October 27, 2026

This M&A and takeover stream captures a heavy day of corporate combination activity on October 27, 2026, spanning large-cap strategic deals, reverse mergers, a spin-off, and micro-cap licensing transactions. The largest signal is Vertiv's roughly $1.45 billion upfront plus up to $1.15 billion earnout for Utility Innovation Holdings, priced near 13x expected 2027 EBITDA and framed around AI data center grid-interconnect constraints. Alamo Group (Econ Engineering, about $158.7 million, roughly 44% EBITDA margin) and GrabAGun (Camfour, about $34.0 million cash-free, debt-free) reflect bolt-on acquisitions of niche, cash-generative distributors and manufacturers. Several filings show a consistent pattern of mixed reported results: Manhattan Associates posted record Q3 revenue (+11% YoY, Cloud +28%) yet operating cash flow fell 26% and DSO rose from 67 to 81 days, while MSG Knickerbockers' spin-off of MSGR cut pro forma revenue from $1,153.8 million to $816.6 million. Micro-cap and SPAC-style transactions (Ecominas, SecureTech, ATII/Forge Nano, Cayson) carry going-concern, dilution, and shell-company disclosures that warrant skepticism. Overall, the stream points to strategic buyers using cash on hand and revolvers for accretive tuck-ins, while reverse recapitalizations and preferred-share consideration dominate the small-cap tail.

10 high priority 10 total filings
· monthly

US Pre-Market SEC Filings Roundup — October 27, 2026

Overnight SEC flow for 2026-10-26 to 2026-10-27 is dominated by routine Form 4 insider grants and small-cap insider buys, with a handful of material events: UPS's mixed Q3 print with a raised full-year guide, Hilton's mixed Q3 with a Q4 RevPAR deceleration and lowered Adjusted EBITDA outlook, Armstrong World's record sales alongside margin pressure, Aclaris's positive Phase 1b ATI-052 data, Woodside's Greater Sunrise sale, and Independent Bank Corp's merger-driven balance-sheet growth alongside rising non-performing loans. Period-over-period data is thin for most filings; where present, the pattern is mixed: top-line growth (UPS +6.7%, Armstrong +11.9%, CenterPoint operating income +33%, Hilton RevPAR +5.8%) coexists with margin pressure from input-cost inflation, tariffs and integration costs. Several reported earnings gains are flattered by non-recurring items (UPS's prior-year $330M sale-leaseback gain, Hilton's World Cup tailwind, Independent Bank's $3.4M MSR mark). Capital-return signals are mixed: Arlo authorized a $100M buyback, Hilton reaffirmed about $3.5B of 2026 capital return, and HSBC USA suspended common dividends in Q3 after $500M a year earlier. Control and activist dynamics are notable in Quanex (Teleios selling and exiting its observer seat), Pluri (CHLP crossing a 35% blocker), and Power REIT (a Series A amendment short of the required majority). Two Form 4 items are rated low-to-moderate materiality and carry limited signal.

31 high priority 19 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — October 26, 2026

Three filings from the S&P 500 Technology stream were published on 2026-10-26: Cadence Design Systems (8-K, earnings furnishing plus a new $2.5B buyback authorization), Applied Materials (8-K, accelerated share purchase agreement for ~20% of Besi), and Lam Research (Form 4, CEO sale under a 10b5-1 plan). All three are in scope. The filings do not disclose period-over-period revenue, margin, or ratio figures, so portfolio-level growth and margin trend analysis cannot be quantified from this set; the enriched period comparison fields are empty for these filings. The dominant theme is capital deployment: Cadence is returning cash via repurchases, while Applied is spending on a strategic semiconductor stake pending antitrust clearance. Insider activity at Lam Research is a routine planned sale rather than a strong conviction signal. Investors should treat the Cadence and Applied items as catalyst-driven and await the Cadence exhibits and the Besi HSR outcome for quantitative follow-through.

2 high priority 1 medium 3 total filings
· daily

Nasdaq 100 Stocks SEC Filings — October 26, 2026

Across the 22 filings for the NASDAQ-100 stream dated 2026-10-26, the dominant themes are heavy insider and executive selling at Intuitive Surgical and Lam Research under Rule 10b5-1 plans, a wave of routine director and executive equity awards and tax withholdings at Costco and Lite Strategy, and two strategically significant events: Applied Materials' accelerated share purchase toward roughly 20% of Besi, and Strategy Inc's bitcoin holdings and STRC preferred buyback. The enriched data does not supply prior-period comparisons, forward guidance, or capital allocation changes for most filings, so period-over-period trend synthesis is limited; the clearest quantified signal is Lam Research's CEO selling 31,400 shares at $227.02 (~$7.13M) after exercising options, and Intuitive Surgical's cumulative insider sales at prices around $443-$453. Strategy Inc reported zero bitcoin accumulation for the week, holding about 848,517 BTC at an average cost near $75,446, with $4.83 billion in USD reserves. Market implications center on insider selling pressure in semiconductor equipment and medtech versus neutral-to-routine governance activity elsewhere. Several filings (DEFA14A, Applied Materials 8-K) lack disclosed economics and require full-document review before conclusions are drawn.

20 high priority 2 medium 22 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — October 26, 2026

This digest covers 42 Schedule 13D/13G and amendment filings dated October 26, 2026, dominated by passive institutional disclosures (Amundi, Royce, Millennium, RA Capital, Viking, Third Rock) that signal routine portfolio rebalancing rather than control intent. The most material developments are control and contest situations: Surgery Partners' Bain-affiliated holders agreeing to roll over ~38% of equity into a going-private merger, XCF Global's EEME stake of 38-45% opposing a reverse split with take-private optionality, Brera Holdings' RBCH (18.3%) publicly criticizing H1 2026 results and pushing for board changes, and APPlife Digital's insider group claiming 60.3% of the company with heavily related-party-driven economics. Capital-structure stress is visible at Capstone Energy+, where Monarch holds 39.8% and a December 7, 2026 note maturity is forcing refinancing talks, and at SenesTech, where an activist is urging an end to dilutive equity raises. Exit and liquidity events cluster around the October 16-19 IPO and follow-on window (City Therapeutics, Alector, TCGX Acquisition Corp. II, Kalaris), with several lock-up expiries and 180-day restrictions now running. The Nathan's Famous merger closing into Smithfield and the Hepion share-for-membership exchange are the largest completed transactions. Period-over-period operating data is largely absent from these ownership filings, so trend synthesis relies on ownership deltas, price paid, and percent-of-class shifts rather than YoY revenue or margin figures.

17 high priority 25 medium 42 total filings
· daily

S&P 500 Financials Sector SEC Filings — October 26, 2026

Across the seven filings dated 2026-10-26, the dominant theme is insider selling at large S&P 500 financial and insurance names, with four Form 4 disclosures (Goldman Sachs, Marsh & McLennan x2, Progressive) showing executives trimming positions, two of them under Rule 10b5-1 plans, which typically signals routine diversification rather than a fundamental warning. The filings contain no period-over-period financial results, guidance, margin, or capital allocation data, so trend comparisons across companies cannot be made from this batch and the enriched fields are largely empty. Citigroup's two filings are housekeeping in nature (exhibit furnishing and a Form 15 for a legacy CMBS trust) and carry no market-moving content. The Progressive Investment Management 13F-HR is the only portfolio-level disclosure, showing a $451.5M technology-weighted book, but it is a third-party fund and offers no period comparison. Overall materiality is low; the actionable signal is the cluster of executive sales at elevated price levels rather than any change in operating fundamentals.

5 high priority 2 medium 7 total filings
· daily

S&P 500 Energy Sector SEC Filings — October 26, 2026

This session was very quiet, with only one enriched filing in scope for the USA S&P 500 Energy stream on 2026-10-26. The sole filing is a Form 4 from Halliburton Co, disclosing a routine director equity award of 961 restricted stock units (RSUs) to David Christopher Hernandez. The filing carries neutral sentiment and a materiality score of 5/10. No period-over-period financial comparisons, guidance changes, M&A transactions, dividend or buyback activity, or insider sales were disclosed, so portfolio-level trend analysis is not possible from this session. The most relevant takeaway is that Halliburton's board continues its standard compensation practice of granting director RSUs, which signals no material change in management or governance posture. Investors should treat this session as a low-information period and rely on the next filing cycle for meaningful sector signals.

1 high priority 1 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — October 26, 2026

The 14 filings for the USA S&P 500 Consumer Staples stream, all dated 2026-10-26, are dominated by Form 4 insider activity rather than financial-statement disclosures, so period-over-period revenue, margin, guidance and capital allocation data are largely absent from this batch. The most material development is a Dollar General 8-K disclosing an FTC and multi-state lawsuit filed October 26, 2026 (following a September 23 draft complaint and settlement order demand), which carries potential material adverse effects on consolidated financials. Procter & Gamble shows the clearest insider selling pattern: CEO Shailesh Jejurikar sold 35,000 shares at $163.09 (~$5.71M) after exercising an equal number of options struck at $78.52, while the Chief Human Resources Officer sold 4,181 shares at $160.71 (~$672K) and a Health Care Group executive sold 4,331 shares at $161.27 (~$698K). Hershey insiders via the Hershey Trust sold shares under a Rule 10b5-1 plan across 14 transactions (~$952K headline value), a pattern consistent with scheduled diversification rather than a conviction signal. Costco filings are almost entirely routine director equity awards (266 shares each) and executive tax withholdings at $1,018.21 per share, which are neutral administrative events. Overall, the batch signals negative insider sentiment at P&G and legal/regulatory risk at Dollar General, with no guidance, dividend or buyback changes disclosed in these filings.

13 high priority 1 medium 14 total filings
· daily

S&P 500 Industrials Sector SEC Filings — October 26, 2026

This digest covers three SEC filings from the S&P 500 Industrials intelligence stream dated 2026-10-26: one FedEx 8-K on a CFO appointment and two Norfolk Southern Form 4 insider filings. None of the filings contains period-over-period financial performance data, forward-looking guidance, capital allocation changes, or M&A terms, so the enriched comparison fields are largely empty and conclusions must be drawn from governance and insider signals rather than financial trends. The most material development is FedEx's leadership transition, with Jamere Jackson, former AutoZone CFO, set to become EVP and CFO on November 30, 2026 after a five-month interim period under Claude Russ. At Norfolk Southern, two senior executives recorded routine equity vesting and tax-withholding transactions at $332.09 per share, with no evidence of open-market selling or buying. Overall, the signals in this batch are neutral, with the main actionable item being the FedEx CFO handover ahead of the effective date.

3 high priority 3 total filings
· daily

US Material Events SEC 8-K Filings — October 26, 2026

This Material Events Monitor batch of 50 US SEC 8-K filings dated 2026-10-26 is dominated by corporate-control and governance events rather than operating results: several large M&A transactions (EQT/Range all-stock merger, Francisco Partners take-private of Weave, RadNet's ONRAD acquisition, Ovintiv's Logan purchase, AAR's credit upsizing for MRO Holdings), a cluster of leadership changes (AutoZone CFO to FedEx, LiveWire CEO exit with restructuring governance, Netscout COO exit, Earth Science Tech CFO exit), and a handful of distress or restatement events (Getty Images Chapter 11, Datavault AI and Panamera non-reliance, Senti's divestiture to CVRs). Because most filings disclose no period-over-period financials, the quantitative trend picture is thin; where data exists it is mixed, with Clearwater Paper showing a narrowed net loss but a sharply lower nine-month Adjusted EBITDA ($18M vs $87M). Market implications center on energy consolidation (EQT/Range targeting >$50B pro forma EV and $325M base synergies), healthcare/SPAC activity, and accounting-quality concerns among micro-caps. Several filings are outside the stream's focus and are excluded below.

50 high priority 50 total filings
· daily

Insider Trading Pulse — October 26, 2026

Across 50 Form 4 insider filings dated 2026-10-26, the digest is dominated by routine equity compensation (RSU/restricted stock awards to directors and officers at ACUITY, Andersons, Vylor, NYT, Solid Biosciences, MillerKnoll and others) rather than open-market conviction trades. Open-market sales are concentrated in a handful of names: Intuitive Surgical director Gary Guthart sold ~$9.08M, MSCI's General Counsel sold ~$1.48M, Dell director Lynn Radakovich sold ~$930K under a 10b5-1 plan, and Procter & Gamble's health care CEO sold ~$698K. The only meaningful open-market accumulation is Bluerock Private Real Estate Fund director Ramin Kamfar, who bought ~$1.37M and ~$758K of shares at ~$12.4-12.5, a clear positive conviction signal. Pledge activity is absent from the filings provided, so the 'Pledge' event type in scope is effectively unrepresented. Tax-withholding dispositions cluster heavily at Applied Optoelectronics (five officers at $77.32 on the same date), which reflects vesting events rather than discretionary selling. Because the filings contain no period-over-period financial metrics, guidance, or capital allocation data, trend analysis is limited to insider behavior and transaction size.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — October 26, 2026

The Dow Jones 30 stream for 2026-10-26 contains five filings, but the enriched data is thin and largely non-comparable: four of five are Form 4 insider-trade notices and one is a 13F-HR from J&J's venture arm (JJDC). No period-over-period financial comparisons, forward guidance, capital allocation changes, M&A terms, or scheduled-event data were supplied for any filing, so portfolio-level growth or margin trend analysis cannot be performed. The dominant theme is insider selling at Procter & Gamble, where three officers (including Chairman/CEO Shailesh Jejurikar) sold roughly $6.4M combined around $160-163 per share, with the CEO's sale preceded by an option exercise at $78.52 that signals a pattern of exercise-and-sell rather than an outright bearish exit. Goldman Sachs' CAO sold a small amount (~$223K combined), which is low materiality. J&J's 13F shows a concentrated early-stage biotech/medtech book led by Protagonist Therapeutics, but it provides no quarter-over-quarter comparison to judge conviction changes. Overall, the signal set is insider-activity driven and should be treated as low-conviction until financial and guidance data are available.

4 high priority 1 medium 5 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — October 26, 2026

Four 8-K filings dated around October 21-26, 2026 were reviewed for the USA Corporate Distress & Bankruptcy stream. Getty Images Holdings, Inc. is the clearest distress event, having filed Chapter 11 petitions in Delaware on October 21, 2026 and secured up to $143 million in DIP financing from Cantor Fitzgerald, with adequate protection payments flowing to prepetition secured lenders. Elme Communities is in an orderly wind-down rather than a bankruptcy: its NYSE delisting is tied to a Plan of Sale and Liquidation, with remaining assets moving to a Liquidating Trust and a Board retaining the right to terminate the plan. Zeo Energy and Eve Holding are listing-compliance events rather than insolvency signals. Zeo received a 180-day extension to April 19, 2027 to cure its $1.00 minimum bid price deficiency, and Eve Holding's NYSE warrant delisting reflects an abnormally low selling price on EVEXW while the common stock (EVEX) continues trading. The filings supplied do not contain period-over-period financial comparisons, insider transaction data, or quantified guidance, so trend analysis is limited to what the narrative discloses. The shared theme is that the stream's scope (bankruptcy, going concern, delisting) is captured most directly by Getty and Elme, with Zeo and Eve representing earlier-stage distress markers.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — October 26, 2026

The 50-filing batch for the Global High Priority Market Events stream is dominated by distress and corporate-control events rather than clean growth stories. Insolvency and creditor-driven processes are prominent (Dharan Infra-EPC CIRP with a CoC meeting on 30 October 2026, Future Consumer's third CoC meeting moved to 27 October, Starlite Components' creditor-driven equity wipeout with a 5 November record date, VXL Instruments' modified resolution plan, and Getty Images' Chapter 11 filing with a $143 million DIP facility). A second cluster is SPAC deadline extensions, redemptions and delisting notices (Bold Eagle, Oaktree III, YHN Acquisition I, Zeo Energy, Krane Shares and ETF Opportunities Trust). Among operating companies, the clearest period-over-period strength is in Mankind Pharma (standalone revenue up 19.3% YoY to ₹3,145.22 Cr, profit up about 27%), APL Apollo Tubes (revenue up 26.6% YoY, PAT up 26.8%) and Paytm's parent One 97 Communications, whose MDR-cap and FEMA show-cause overhang offsets operating momentum. Weakness is concentrated in DCM Shriram (Q2 PAT down 14.3% YoY, underlying pre-exceptional profit down 23.7%, flattered by a ₹474.30 Cr one-off tax credit) and Baba Arts (core sales essentially nil, net profit down about 49%). Corporate-control events are the other big theme: Hittco Tools' promoter takeover and diversification, Weave Communications' $650 million take-private at $7.40 per share, and Senti Biosciences' divestiture to a CVR-only merger. Overall, the batch skews negative for minority shareholders, with distressed-restructuring and delisting outcomes outnumbering growth catalysts.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — October 26, 2026

The October 26, 2026 digest covers 50 SEC filings spanning M&A, biotech clinical data, SPAC activity, 13F holdings disclosures, and foreign private issuer administrative notices. The dominant market-moving developments are the all-stock EQT/Range Resources merger (pro forma EV above $50 billion, $325 million base synergies), the Amanat/Corxel SPAC deal at a $200 million implied equity value, and Elme Communities' NYSE delisting under a plan of liquidation. Period-over-period data is sparse across the set, but Ladder Capital shows a clear divergence between a one-time real estate gain driving Q3 EPS up to $0.53 from $0.15 and a 15.6% YoY decline in quarterly net interest income as interest expense rose 37.3%. Biotech readouts (Eikon EIK1001 ORR 63.1%, ArriVent ARR-217, NovaBridge givastomig, Phathom exclusivity litigation) and balance-sheet stress names (Expion360 Baby Shelf ATM, Cyber Enviro-Tech equity line) form a clear bifurcation between capital-raising risk and pipeline optionality. Several large-cap Asian issuers (SK hynix, KB Financial) are executing material buybacks, and SK hynix's Q3 earnings on October 28 may clarify a reported special dividend. The 13F-heavy tape shows broadly passive, mega-cap-concentrated institutional positioning with little incremental signal.

13 high priority 37 medium 50 total filings